Table 1. Clinical and demographical characteristics of patients.
| Characteristics | Episodes, N = 65 | (%) |
|---|---|---|
| Demographics | ||
| Age–years, median (IQR) | 49 | (35.3–62.6) |
| Elderly (age > 65a) | 13 | (20) |
| Female sex | 31 | (47.7) |
| Male sex | 34 | (52.3) |
| Comorbidities | 42 | (64.6) |
| Hypertension | 16 | (24.6) |
| Diabetes mellitus | 7 | (10.8) |
| Cardiac failure | 5 | (7.8) |
| Smoking | 18 | (27.7) |
| Underlying disease | ||
| Acute myelogenous leukemia | 41 | (63.1) |
| Acute lymphoblastic leukemia | 16 | (24.6) |
| Lymphomas | 4 | (6.1) |
| Other myeloproliferative or lymphoproliferative disorders | 4 | (6.1) |
| Status of haematological malignance | ||
| Newly diagnosed–first line treatment | 24 | (36.9) |
| Refractory | 16 | (24.6) |
| Relapsed | 13 | (20) |
| Remission | 12 | (18.5) |
| Hematopoietic stem cell transplantation | 18 | (27.7) |
| • Allogenic: HLA compatible sibling | 5 | (7.7) |
| • Allogenic: matched-unrelated donor | 4 | (6.2) |
| • Allogenic: haploidentical | 4 | (7.7) |
| • Autologous | 5 | (6.2) |
| Conditioning regimens a | ||
| Reduced intensity conditioning regimen | 6 | (33.3) |
| Myeloablative | 3 | (16.7) |
| Non-myeloablative | 9 | (50) |
| Clinical characteristics and exposures | ||
| ECOG > 2 | 7 | (10.8%) |
| Chemotherapyb | 59 | (90.8) |
| Central venous linec | 59 | (90.8) |
| Antifungal prophylaxisb | 65 | (100) |
| Anti-mold prophylaxisb | 12 | (18.5) |
| Antibacterial prophylaxis–quinoloneb | 55 | (84.6) |
| Previous therapeutic antimicrobial therapyb | 60 | (92.3) |
| Fourth generation cephalosporins exposureb | 38 | (58.5) |
| Carbapenems exposureb | 49 | (75.4) |
| Polymyxin B exposureb | 11 | (16.9) |
| Neutropeniad | 61 | (93.8) |
| Severe neutropeniae | 57 | (87.7) |
Clinical and demographical characteristics of 65 carbapenem-resistant Klebsiella pneumoniae bloodstream infections among patients with haematological malignances and hematopoietic stem cell transplant recipients. Notes: HLA–Human Leucocyte Antigen; IQR–Interquartile range.
aconsidering only hematopoietic stem cell transplant recipients
bIn the 30 days preceding CRKp-BSI
cAt the CRKp-BSI onset
dNeutrophil count below 500 cel./mm3
eNeutrophil count below 100 cel./mm3